C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

Adult CIRB - Early Phase Emphasis Meeting Agenda

November 17, 2026

I New Study ReReview

10740, A Phase 2 Trial of IMC-F106C, a PRAME Targeted ImmTAC, in Rare Cancers (Version Date 10/22/26)

II Continuing Review

EAY131, Molecular Analysis for Therapy Choice (MATCH) (Version Date 12/05/25)

III Continuing Review

EAY131-H, MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, Colorectal Adenocarcinoma, and Non-Small Cell Lung Cancer) (Version Date 12/05/25)

IV Continuing Review

EAY131-J, MATCH Treatment Subprotocol J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ, and Non-Colorectal Cancers with HER2 Amplification (Version Date 10/16/24)

V Continuing Review

EAY131-Z1D, MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Version Date 08/04/25)

VI Continuing Review

EAY131-Z1E, MATCH Treatment Subprotocol Z1E: Larotrectinib (LOXO-101) in Patients with Tumors with NTRK Fusions (Version Date 11/10/22)

C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

VII Continuing Review

EAY131-A, MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment (Version Date 09/15/20)

VIII Continuing Review

EAY131-B, MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations (Version Date 07/10/19)

IX Continuing Review

EAY131-C1, MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification (Version Date 08/19/20)

X Continuing Review

EAY131-C2, MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion (Version Date 08/19/20)

XI Continuing Review

EAY131-E, MATCH Treatment Subprotocol E: Osimertinib (AZD9291) in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR (Version Date 07/16/21)

XII Continuing Review

EAY131-F, MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements (Version Date 03/11/19)

C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

XIII Continuing Review

EAY131-G, MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer) (Version Date 01/25/19)

XIV Continuing Review

EAY131-I, MATCH Treatment Subprotocol I: GDC-0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA Mutation but without KRAS Mutation or PTEN Loss (Version Date 11/10/22)

XV Continuing Review

EAY131-K1, MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications (Version Date 03/11/19)

XVI Continuing Review

EAY131-K2, MATCH Treatment Subprotocol K2: Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations or Fusions (Version Date 08/19/20)

XVII Continuing Review

EAY131-L, MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations (Version Date 08/19/20)

XVIII Continuing Review

EAY131-M, MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations (Version Date 08/19/20)

C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

XIX Continuing Review

EAY131-N, MATCH Treatment Subprotocol N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Mutation or Deletion, with PTEN Expression on IHC (Version Date 02/06/17)

XX Continuing Review

EAY131-P, MATCH Treatment Subprotocol P: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Loss by IHC (Version Date 02/06/17)

XXI Continuing Review

EAY131-Q, MATCH Treatment Subprotocol Q: Ado-trastuzumab Emtansine in Patients with Tumors with HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas) (Version Date 08/19/20)

XXII Continuing Review

EAY131-R, MATCH Treatment Subprotocol R: Phase II Study of Trametinib in Patients with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations (Version Date 11/10/22)

XXIII Continuing Review

EAY131-S1, MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients with Tumors with NF1 Mutations (Version Date 11/10/22)

XXIV Continuing Review

EAY131-S2, MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 Mutations (Version Date 08/19/20)

C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

XXV Continuing Review

EAY131-T, MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations (Version Date 08/19/20)

XXVI Continuing Review

EAY131-U, MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss (Version Date 07/10/19)

XXVII Continuing Review

EAY131-V, MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) (Version Date 11/10/22)

XXVIII Continuing Review

EAY131-W, MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway (Version Date 05/16/18)

XXIX Continuing Review

EAY131-X, MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations (Version Date 02/06/17)

XXX Continuing Review

EAY131-Y, MATCH Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations (Version Date 01/05/22)

C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

XXXI Continuing Review

EAY131-Z1A, MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations (Version Date 05/16/18)

XXXII Continuing Review

EAY131-Z1B, MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification (Version Date 06/21/18)

XXXIII Continuing Review

EAY131-Z1C, MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification (Version Date 10/09/20)

XXXIV Continuing Review

EAY131-Z1F, MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed) (Version Date 08/12/19)

XXXV Continuing Review

EAY131-Z1G, MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result (Version Date 07/16/21)

XXXVI Continuing Review

EAY131-Z1H, MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC (Version Date 08/19/20)

C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

XXXVII Continuing Review

EAY131-Z1I, MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations (Version Date 11/10/22)

XXXVIII Continuing Review

EAY131-Z1K, MATCH Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations (Version Date 11/10/22)

XXXIX Continuing Review

EAY131-Z1L, MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations (Version Date 08/19/20)

XL Continuing Review

EAY131-Z1M, Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy (Version Date 01/05/22)
